Core Viewpoint - The investigation reveals that several psychiatric hospitals in Xiangyang and Yichang are illegally admitting normal individuals as patients to exploit insurance funds, turning them into revenue-generating tools for the hospitals [1][4][5]. Group 1: Hospital Practices - Hospitals are engaging in practices such as admitting healthy individuals under false pretenses, with some even employing internal staff to pose as patients [4][5]. - These institutions are manipulating diagnoses to fit insurance reimbursement criteria, such as misclassifying alcohol dependence as a mental disorder to secure funding [4][5]. - Patients are subjected to minimal treatment, with reports indicating that some only receive occasional medication and basic tests, while the hospitals charge exorbitant fees for services not rendered [5]. Group 2: Regulatory Response - A joint investigation team has been established by the Yichang government to address the fraudulent practices, promising to handle the situation according to the findings and keep the public informed [2]. - The National Medical Insurance Bureau has emphasized a "zero tolerance" policy towards fraud, implementing a comprehensive regulatory framework to combat various forms of insurance fraud across healthcare institutions [9]. Group 3: Broader Implications - The fraudulent activities not only harm the patients who genuinely need care but also undermine the overall healthcare system, affecting the quality of medical services and insurance benefits for all insured individuals [1][6]. - The prevalence of fraud in psychiatric hospitals reflects a larger issue within the healthcare sector, where similar deceptive practices are reported across various medical institutions and retail pharmacies [6][7]. Group 4: Future Directions - Experts suggest that the exposure of these fraudulent practices presents an opportunity for reform, advocating for stricter regulations and innovative payment models to reduce the potential for fraud [5][9]. - The integration of big data from multiple sectors is seen as a crucial step in enhancing oversight and ensuring that legitimate patients receive the care they need while deterring fraudulent activities [9].

本文字数：2121，阅读时长大约4分钟 2026.02. 03 作者 | 第一财经 秦新安 这是本月国家医保局曝光的第四起典型回扣案。在此之前，国家医保局已先后曝光黑龙江省双丰林业局职工医院内科医生党某海犯非国家工作人员受贿 罪案、重庆康荣医疗设备有限公司实际控制人王某向重庆某医院院长孙某行贿案，以及山东某医用高分子制品公司业务员慈某龙向普洱市人民医院工作 人员行贿案。几起案件暴露了医药商业贿赂的猖獗，也展示了医保部门打击医药商业贿赂、维护医保基金安全的决心。 国家医保局指出，医药商业贿赂本质上是通过给予不正当利益影响处方权，干扰正常诊疗行为，妨碍公平竞争，加重医药负担，使得医药产品销售从实 际临床价值和产品竞争力的竞争，转为以高返点和高回扣驱动的不当竞争。陕西李某受贿案就呈现医药商业贿赂的典型特征。一方面，受贿方利用科室 主任对科室使用耗材的决策权，在众多可选产品中优先选用给予高额回扣的贴牌耗材；另一方面，行贿方将事先约定回扣计入供货成本，最终通过医保 基金与患者自付"埋单"。 医药商业贿赂屡禁不止，背后是复杂的利益链条与制度漏洞。长期以来，在部分医疗领域，特别是高值耗材与药品销售中，"带金销售"成为一些企 ...

Core Viewpoint - The article highlights the serious issue of commercial bribery in the medical sector, emphasizing the need for stringent measures to combat it and protect public health and the integrity of the healthcare system [1][2][3]. Group 1: Cases of Bribery - The National Healthcare Security Administration (NHSA) reported a case involving a hospital director in Shaanxi who illegally accepted 2.72 million yuan in bribes, primarily from orthopedic consumables [1]. - This case is part of a broader trend, with the NHSA exposing multiple instances of bribery in the medical field, indicating a rampant issue that undermines fair competition and increases medical costs [1][2]. Group 2: Nature of Commercial Bribery - Commercial bribery in the medical field distorts prescription rights and interferes with normal medical practices, leading to increased costs for patients and the healthcare system [2]. - The bribery cases reveal a pattern where suppliers offer high rebates to secure contracts, which ultimately inflates product prices and burdens patients and insurance funds [2][3]. Group 3: Systemic Issues and Reforms - The article discusses the systemic issues that allow commercial bribery to persist, including complex interest chains and regulatory loopholes, particularly in high-value consumables and pharmaceuticals [2][3]. - The NHSA has been increasing efforts to combat commercial bribery through administrative and criminal measures, emphasizing the need for comprehensive reforms in the procurement system to reduce incentives for bribery [3][4]. Group 4: Recommendations for Action - To effectively eliminate commercial bribery, a multi-faceted approach is necessary, including strict penalties for both bribers and recipients, improved internal decision-making processes in medical institutions, and enhanced transparency in procurement [4][5]. - The article stresses the importance of enforcing the principle of "joint investigation of bribery and acceptance" and the "dual penalty system" for companies and individuals involved in bribery [4][6]. Group 5: Broader Implications - The prevalence of commercial bribery not only harms public finances but also jeopardizes public health and social equity, as each bribe can lead to unnecessary medical expenses and inappropriate treatment choices [6]. - The ongoing efforts to combat medical commercial bribery are crucial for purifying the industry and safeguarding the health and welfare of the public [6].

Core Viewpoint - The case involving Li, a hospital director in Shaanxi, highlights significant corruption in the medical supply industry, where bribes were accepted in exchange for preferential treatment in the procurement of medical supplies and drugs, indicating a need for regulatory reforms in the sector [1][4]. Group 1: Case Details - Li was accused of accepting a total of 2,720,548 yuan in bribes from medical supply vendors, including 2,468,958 yuan from supplier Jia, 231,580 yuan from supplier Sun, and 20,010 yuan from pharmaceutical representative Jiang [1][3]. - The bribes were structured as a percentage of the total supply value, with Jia offering a 35% kickback and Sun offering 30%, indicating a systemic issue of inflated pricing in the medical supply chain [2][4]. - The court sentenced Li to six years in prison and imposed a fine of 400,000 yuan for his involvement in these corrupt practices [3]. Group 2: Industry Implications - The case exemplifies how medical commercial bribery undermines fair competition and increases healthcare costs, as the inflated prices of medical supplies are driven by kickbacks rather than clinical value [4]. - The involvement of substandard or rebranded products in the supply chain raises concerns about the quality and efficacy of medical supplies used in clinical settings [4]. - The National Healthcare Security Administration plans to implement credit evaluations and corrective measures for untrustworthy companies to safeguard healthcare funds and ensure compliance within the industry [4].

Core Viewpoint - The article discusses a bribery case involving a hospital director in Shaanxi Province, highlighting the issue of kickbacks in the medical supply industry and the need for regulatory oversight to ensure fair competition and protect healthcare funds [3][6]. Group 1: Case Details - Li, the director of a bone surgery department, received a total of 2.7205 million yuan in bribes, primarily from orthopedic supply kickbacks [3][4]. - Li accepted 2.469 million yuan from supplier Jia, who promised a 35% kickback on the total supply amount, leading to the use of Jia's products in surgeries from July 2014 to March 2017 [4][5]. - Li also received 231,600 yuan from supplier Sun, who offered a 30% kickback, with the supply agreement in place from January 2018 to January 2019 [5]. Group 2: Implications and Regulatory Actions - The National Healthcare Security Administration (NHSA) stated that medical bribery distorts prescription rights and disrupts normal medical practices, leading to inflated prices for medical supplies [6]. - The NHSA plans to guide local healthcare authorities in evaluating the credit of dishonest companies and enforcing corrective measures to protect healthcare funds [6]. - In 2023, the NHSA has already exposed four bribery cases, indicating a trend of corruption in the pharmaceutical and medical supply sectors [7].

Core Viewpoint - The National Healthcare Security Administration (NHSA) has exposed multiple cases of kickbacks in the medical industry, particularly in the fields of pharmaceuticals and medical supplies, highlighting the prevalence of corruption and its impact on healthcare costs and competition [3][4]. Group 1: Case Details - A case involving Li, the director of an orthopedic hospital in Shaanxi, revealed that he illegally accepted a total of 2.7205 million yuan in kickbacks, primarily from orthopedic supplies [1]. - Li received 2.469 million yuan from supplier Jia, who promised a 35% kickback on the total supply amount, leading to the procurement of supplies worth 7.0546 million yuan from July 2014 to March 2017 [1]. - Another supplier, Sun, paid Li 231,600 yuan in kickbacks from January 2018 to January 2019, with a total supply value of 772,200 yuan, despite Li lacking the authority to choose suppliers [2]. Group 2: Implications and Responses - The NHSA stated that medical commercial bribery undermines fair competition and increases healthcare costs, as kickbacks can inflate the prices of medical products by at least one-third [3]. - The NHSA plans to guide local healthcare authorities in evaluating the creditworthiness of involved companies and enforce corrective measures against those that fail to comply [3]. - In 2023, the NHSA has already exposed four kickback cases, indicating a significant issue within the pharmaceutical and medical supply sectors [3].

Core Viewpoint - The article discusses a case of corruption involving a hospital director in Ankang City, Shaanxi Province, who was found guilty of accepting bribes totaling 2,720,548 yuan from medical suppliers, highlighting issues of medical commercial bribery and its impact on healthcare costs and competition [2][5]. Group 1: Case Details - The hospital director, Li, accepted a total of 2,720,548 yuan in bribes from various medical suppliers, including 2,468,958 yuan from supplier Jia for medical consumables, which was used for personal expenses such as purchasing and renovating a villa [2][3]. - Li also received 231,580 yuan from supplier Sun, who promised a 30% kickback on the total supply amount, which Li used to repay personal loans [3]. - Additionally, Li accepted 20,010 yuan from pharmaceutical supplier Jiang, which he used to promote a specific drug within the hospital [4]. Group 2: Implications of Corruption - The case illustrates how medical commercial bribery undermines fair competition and increases healthcare costs, as the kickback system distorts the procurement process, leading to inflated prices for medical supplies [5]. - The article emphasizes the necessity for centralized procurement of orthopedic consumables to mitigate such corrupt practices and ensure the integrity of the healthcare system [6].

Group 1 - The article highlights the case of She Qian, a former director of the laboratory department at a hospital in Chongqing, who is under investigation for corruption and bribery related to real estate purchases [1][2][3] - She Qian allegedly received over 1,042,000 RMB in bribes from pharmaceutical companies, with a significant portion used to fund her real estate investments [6][10] - The investigation revealed that She Qian utilized her position to accept kickbacks and benefits from medical companies, often requiring them to finance her property purchases to create a "firewall" against direct evidence of corruption [4][7][8] Group 2 - The National Medical Insurance Administration has been actively disclosing multiple cases of corruption in the medical field, indicating a widespread issue involving various stakeholders, including medical device companies and hospital leaders [11][12] - Recent reports show that the amounts involved in these corruption cases range from 35,000 RMB to 8 million RMB, with some cases spanning over a decade [11][12] - Experts suggest that the root causes of these corruption issues stem from information asymmetry, weak regulatory frameworks, and a lack of compliance awareness among involved parties [15][16]

Core Viewpoint - The National Healthcare Security Administration reported on the bribery case involving a sales representative from a medical polymer products company, highlighting extensive bribery practices within a public hospital that compromised fair competition and increased medical costs [1][6][10]. Summary by Sections Bribery Details - The accused, Ci Mou Long, bribed staff at the Pu'er City People's Hospital with a total of RMB 3,950,000 in cash and 200 grams of gold bars, along with various medical supplies as kickbacks [1][6]. - From 2012 to 2020, Ci Mou Long made 11 payments totaling RMB 290,000 and USD 9,900 to the hospital's chief accountant for favorable payment processing [1][2]. - Over the years, multiple hospital staff members received kickbacks for various medical supplies, including RMB 1,191,243 in total from 2012 to 2018 [1][6]. Legal Consequences - Ci Mou Long was sentenced to 2 years and 6 months in prison and fined RMB 200,000 for bribery and corporate bribery [10]. - The case reflects ongoing issues in the medical supply industry, where improper incentives disrupt normal medical practices and inflate costs [6][10]. Industry Implications - The National Healthcare Security Administration is taking steps to regulate the procurement of medical supplies, aiming to reduce inflated prices and alleviate the financial burden on patients [10]. - The case underscores the need for stricter oversight and accountability in the medical supply sector to ensure fair competition and protect healthcare funds [6][10].

Core Viewpoint - The case highlights the issue of commercial bribery in the pharmaceutical industry, specifically involving a sales representative from Shandong Weigao Group Medical Polymer Co., Ltd., who engaged in bribery to influence prescription practices and disrupt fair competition in the healthcare sector [5][7]. Group 1: Bribery Details - The sales representative, Ci Mou Long, was found guilty of bribing staff at the Pu'er People's Hospital with a total of RMB 1,195,243 in cash and goods, including cash payments of RMB 395,000 and USD 9,900, as well as a gold bar weighing 200 grams [5][8]. - Between 2012 and 2020, Ci Mou Long made multiple payments to various hospital staff, including a total of RMB 290,000 in cash and a gold bar to the hospital's chief accountant, Liu Mou Wen, for facilitating payment settlements [8]. - The bribery involved various medical supplies, with cash kickbacks totaling RMB 408,200 and 500 supermarket vouchers distributed among nursing staff across different departments [13]. Group 2: Legal Consequences - Ci Mou Long was sentenced to 2 years and 6 months in prison and fined RMB 200,000 for his actions [7]. - The National Healthcare Security Administration (NHSA) plans to guide local healthcare authorities in conducting credit evaluations and enforcing measures against untrustworthy companies to protect healthcare fund security [7]. Group 3: Industry Implications - The NHSA has been actively reporting multiple cases of commercial bribery in the pharmaceutical sector to warn against unethical practices that undermine the integrity of medical services and increase healthcare costs [6].